Unmet needs, uncommon commitment: The shift toward investment in rare diseases

January 19, 2017 Erin Righetti

Join biotech leaders, emerging innovators, investors and patient advocacy group representatives for a candid, interactive and enlightening panel discussion about the evolving landscape in rare disease drug discovery and development. The panel discuss how approaches to rare disease research, drug development, commercialization and investment have changed in recent years, and why and how they’ve chosen to pursue leadership and innovation in rare diseases.

 

Moderator: Alison Silva – Critical Outcome Technologies

  • Debra Miller – CureDuchenne
  • Henri Termeer – Formerly Genzyme; Aura Biosciences
  • Phil Vickers – Shire
  • Flemming Ornskov – Shire

About the Author

Erin Righetti

Editor-in-Chief, Insight

Follow on Twitter More Content by Erin Righetti
Previous Video
Biotech Showcase™ 2017: Payer environment will impact biopharma prospects in 2017
Biotech Showcase™ 2017: Payer environment will impact biopharma prospects in 2017

An increased focus on the need to access and develop truly transformational medicines was a key theme in th...

Next Video
Biotech Showcase™ 2017: Unmet needs, uncommon commitment: The shift toward investment in rare diseas
Biotech Showcase™ 2017: Unmet needs, uncommon commitment: The shift toward investment in rare diseas

Join biotech leaders, emerging innovators, investors and patient advocacy group representatives for a candi...